Phaseline

Targets › ATP4A

ATP4A (Potassium-transporting ATPase alpha chain 1): drug programs, companies and trials

23 programs from 21 companies in 64 trials: 26 Phase 4, 20 Phase 2, 14 Phase 3, 4 Phase 1; Gastroenterology, Oncology, Infectious disease; next expected readout Nov 2026.

The catalytic subunit of the gastric H(+)/K(+) ATPase pump which transports H(+) ions in exchange for K(+) ions across the apical membrane of parietal cells. Uses ATP as an energy source to pump H(+) ions to the gastric lumen while transporting K(+) ion from the lumen into the cell (By similarity). (UniProt, P20648)

Open in Phaseline: the race on ATP4A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Odense University HospitalCapsule FMT
Amiloride-sensitive sodium channel, ENaC blocker
GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1GPhase 4Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women …Dec 2026
Stephen FirkinsOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 4Marginal UlcerMar 2027
Prof Urs ZinggEsomeprazol MUT Sandoz® 40mg tablet
Proton pump inhibitor (PPI)
ATP4A, ATP4BPhase 4ObesityDec 2027
Dow University of Health SciencesDexlansoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 4H. Pylori Gastrointestinal Disease–
Dow University of Health SciencesLansoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 4H. Pylori Gastrointestinal Disease–
Carnot LaboratoriesTegoprazan
Potassium-transporting ATPase blocker
ATP4A, ATP4BPhase 4Gastroesophageal Reflux Disease; Helicobacter Pylori Infection Chronic Gastrit; Coronary Artery Disease; Ischemic Stroke …–
Incheon St.Mary's HospitalZastaprazan
Potassium-competitive acid blocker (P-CAB)
ATP4APhase 4GERD–
Cinclus Pharma HoldingLinaprazan glurate
Potassium-competitive acid blocker (P-CAB); H+/K+-ATPase inhibitor
ATP4APhase 3GERD (Gastroesophageal Reflux Disease); PharmacokineticsNov 2026
Phathom PharmaceuticalsVonoprazan
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Symptomatic Non-erosive Gastroesophageal Reflux Disease; Eosinophilic Esophagitis; Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer; HELICOBACTER PYLORI INFECTIONS …Dec 2026
Nanjing First Hospital, Nanjing Medical UniversityKeverprazan
P-CAB (potassium-competitive acid blocker)
ATP4APhase 3Helicobacter InfectionJun 2027
Il-Yang Pharm.Ilaprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Peptic UlcerAug 2027
Ottawa Hospital Research InstituteOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Venous ThromboembolismDec 2027
Sherief Abd-ElsalamPantoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3OncologyDec 2030
National Cancer Center, KoreaLansoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Gastric CancerDec 2035
AstraZenecaEsomeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Erosive Esophagitis; Liver Cirrhosis; Helicobacter Pylori Infections; Radiation Esophagitis …–
Norfolk and Norwich University Hospitals NHS Foundation TrustLansoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Idiopathic Pulmonary Fibrosis–
The University of Texas Health Science Center, HoustonPantoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Acute Kidney InjuryDec 2026
United States Naval Medical Center, Portsmouthpantoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Postoperative Nausea and VomitingDec 2026
Wake Forest University Health SciencesOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Prostate CancerFeb 2028
Universidad Autonoma de Nuevo LeonOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Morbidity–
Universidad Autonoma de Nuevo LeonPantoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Morbidity–
Murdoch Childrens Research InstituteOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 1Hodgkin LymphomaNov 2026
Caroline Sameromeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 1Healthy Volunteers–

Conditions

HELICOBACTER PYLORI INFECTIONS (5) Helicobacter Pylori Infection (4) H. Pylori Infection (4) H. Pylori Gastrointestinal Disease (3) Acute Kidney Injury (2) Morbidity (2) Obesity (2) Oncology (2) Symptomatic Non-erosive Gastroesophageal Reflux Disease (1) Eosinophilic Esophagitis (1) Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer (1) Gastroesophageal Reflux Disease (GERD) (1)

Modalities

small molecule (21), protein or peptide (1)

Companies

Universidad Autonoma de Nuevo Leon (2) Dow University of Health Sciences (2) Phathom Pharmaceuticals (1) Il-Yang Pharm. (1) Incheon St.Mary's Hospital (1) The University of Texas Health Science Center, Houston (1) Nanjing First Hospital, Nanjing Medical University (1) Ottawa Hospital Research Institute (1) Murdoch Childrens Research Institute (1) Prof Urs Zingg (1) Sherief Abd-Elsalam (1) Wake Forest University Health Sciences (1) Stephen Firkins (1) Odense University Hospital (1) Norfolk and Norwich University Hospitals NHS Foundation Trust (1) Carnot Laboratories (1) National Cancer Center, Korea (1) Cinclus Pharma Holding (1) United States Naval Medical Center, Portsmouth (1) Caroline Samer (1)

Related targets

ATP4B (20) GLP1R (1) CTLA4 (1) FKBP1A (1) TNF (1) PDCD1 (1) SCNN1A (1) SCNN1B (1) SCNN1G (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.